Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients

American Journal of Medicine

Volumn 108, Issue 2, 2000, Pages 165-167

  Tincani, Enrico ^a   Bertoni, Giorgio ^b   Silingardi, Mauro ^a   Ghirarduzzi, Angelo ^a   Bedogni, Giuliano ^b   Iori, Ido ^a  

^a Arcispedale Santa Maria Nuova   (Italy)

^b Servizio di Endoscopia Digestiva   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTICOAGULANT AGENT; AZITHROMYCIN; CLARITHROMYCIN; PANTOPRAZOLE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; AGED; AMOXICILLIN; ANTI-ULCER AGENTS; ANTICOAGULANTS; BENZIMIDAZOLES; CARDIOVASCULAR DISEASES; DUODENUM; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; PROSPECTIVE STUDIES; SULFOXIDES;

EID: 0033955790     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00412-X     Document Type: Article

References (28)

1. Palareti G., Leali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment an inception-cohort, prospective collaborative study (ISCOAT) . Lancet. 348:1996;423-428.
2. Choudari C.P., Rajgopal C., Palmer K.R. Acute gastrointestinal haemorrhage in anticoagulated patients diagnoses and response to endoscopic treatment . Gut. 35:1994;464-466.
3. Marshall B.J. Helicobacter pylori. Am J Gastroenterol. 89:1994;S116-S128.
4. International Agency for research on cancer: schistosomes liver flukes and Helicobacter pylori. Lyon: IARC, 1994;61:177-241.
5. Beyth R.J., Quinn L.M., Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 105:1998;91-99.
6. 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut. 40:1997;459-462.
7. 13C-urea breath test for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol. 3:1991;915-921.
8. Goddard A.F., Logan R.P.H. Review article urea breath test for detecting Helicobacter pylori . Aliment Pharmacol Ther. 11:1997;641-649.
9. Kearon C., Hirsh J. Management of anticoagulation before and after elective surgery. NEJM. 21:1997;1506-1511.
10. Raschhe R.A., Reilly B.M., Guidry J.R., et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med. 119:1993;874-881.
11. Fisher R.S., Parkman H.P. Management of nonulcer dyspepsia. NEJM. 339:1998;1376-1381.
12. Jones R.H., Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther. 11:1997;541-546.
13. Bertoni G., Sassatelli R., Nigrisoli E., et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori a controlled trial versus omeprazole plus amoxicillin . Am J Gastroenterol. 2:1996;258-263.
14. Moayyedi P., Sahay P., Tompkins D.S., Axon A.T.R. Efficacy and optimum dose of omeprazole in a new one week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol. 7:1995;835-840.
15. Wells P.S., Holbrook A.M., Crowther N.R., Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 121:1994;676-683.
16. Hirsh J., Dalen J.E., Anderson D.R., et al. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 114:1998;445S-469S.
17. Nahata M. Drug interactions with azithromycin and the macrolides an overview . J Antimicrob Chemother. 37:(suppl C):1996;133-142.
18. Steinijans V.W., Huber R., Hartmann M., et al. Lack of pantaprazole drug interactions in man an updated review . Int J Clin Pharmacol Ther. 34:(suppl 1):1996;S31-S50.
19. Recker M.W., Kier K.L. Potential interaction between clarithromycin and warfarin. Ann Pharmacother. 31:1997;996-998.
20. Current European concepts in the management of Helicobacter pylori infection. Maastricht Consensus Report. Gut. 1997;41:8-13.
21. Marshall B.J. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA. 13:1995;1064-1066.
22. Guidelines on oral anticoagulation, third edition. Br J Haematol. 1998;101:374-387.
23. Chiquette E., Amato M.G., Bussey H.I. Comparison of an anticoagulation clinic with usual medical care. Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 158:1998;1641-1647.
24. Landefeld C.S., Goldman L. Major bleeding in outpatients treated with warfarin incidence and prediction by factors known at the start of outpatient therapy . Am J Med. 87:1989;144-152.
25. Beyth R.J., Quinn L.M., Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 105:1998;91-99.
26. Howden C.W. Clinical expression of Helicobacter pylori infection. Am J Med. 100:1996;27S-34S.
27. Webb P.M., Knight T., Graves S., et al. Relation between infection with Helicobacter pylori and living conditions in childhood evidence for person to person transmission in early life . BMJ. 308:1994;750-753.
28. Anand B.S., Raed A.K., Malaty H.M., et al. Low point prevalence of peptic ulcer in normal individuals with Helicobacter pylori. Am J Gastroenterol. 91:1996;1112-1115.